Shortened duration of human chorionic gonadotrophin surveillance following complete or partial hydatidiform mole: evidence for revised protocol of a UK regional trophoblastic disease unit

Sebire, Neil J.; Foskett, Marianne; Short, Deborah J.; Savage, Philip; Stewart, Wilson W.; Thomson, Margaret; Seckl, MJ

doi:10.1111/j.1471-0528.2007.01320.x

Cited by 55 publications

(38 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recent data show that GTN rarely occurs after the hCG has spontaneously returned to normal and hence contraception for only 6 months rather than 1 year is now recommended [3,17]. Termination of pregnancy is not indicated if accidental pregnancy occurs during surveillance after the hCG level has returned to normal.…”

Section: Molar Pregnancymentioning

confidence: 99%

Update on the diagnosis and management of gestational trophoblastic disease

Ngan

Seckl

Berkowitz

et al. 2015

Intl J Gynecology & Obste

251

403

View full text Add to dashboard Cite

Section: Molar Pregnancymentioning

confidence: 99%

Update on the diagnosis and management of gestational trophoblastic disease

Ngan

Seckl

Berkowitz

et al. 2015

Intl J Gynecology & Obste

251

403

View full text Add to dashboard Cite

“…The average number of chemotherapy cycles received for normalization of serum b-hCG levels was 4.82 (2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12).In high-risk group, patients received on average 5.1 cycles (3-8), while in low-risk group, patients received on average 4.46 cycles (2-12) for normalization of serum b-hCG levels.…”

Section: Resultsmentioning

confidence: 99%

“…Treatment was continued for three cycles after normalization of Serum b-hCG in high-risk group and for two cycles in low-risk group. After the last chemotherapy cycle, patients were kept on regular follow-up using regular b-hCG monitoring as per standard guidelines [1,2]. Specifically, b-hCG level was measured at 6-8 weeks after the end of any pregnancy to exclude disease recurrence [3,4].…”

Section: Methodsmentioning

confidence: 99%

Gestational Trophoblastic Neoplasia: Experience from a Tertiary Care Center of India

Hussain

Aziz

Bhatt

et al. 2015

J Obstet Gynecol India

View full text Add to dashboard Cite

Aims Gestational trophoblastic neoplasia (GTN) comprise a spectrum of interrelated conditions originating from the placenta. With sensitive assays for human chorionic gonadotropin (b-hCG) and current approaches to chemotherapy, most women with GTN can be cured with preservation of reproductive potential. The purpose of this analysis was to address the outcome of GTN in patients from a tertiary care center of India. Materials and MethodsWe undertook a retrospective and prospective review of GTN cases treated at our center over a period of 7 years from 2008 to 2014. Patients of GTN were assigned to low-risk or high-risk categories as per the FIGO scoring system. The low-risk group was treated with combination of actinomycin-D and methotrexate and the high-risk group received the Etoposide, Methotrexate, Actinomycin-D/ Cyclophosphamide, Vincristine (EMA/ CO) regimen. Salvage therapy was Etoposide, Paclitaxel / Paclitaxel, Cisplatin (EP/TP). Treatment was continued for three cycles after normalization of b-hCG level, after which the patients were followed up regularly. Results In total, 41 GTN patients were treated at our institution during the above period; 17 were in the low-risk and 24 were in the high-risk category. The lung was the most common site of metastasis. All low-risk patients achieved complete remission. Among high-risk patients, one patient died while receiving first cycle chemotherapy, one patient relapsed, and 22 patients achieved complete Conclusion Risk-stratified treatment of GTN was associated with acceptable toxicity and resulted in outcome that was comparable with international standards. The use of two-drug combination in low-risk patients is a better option especially in developing countries.

show abstract

“…Les mécanismes des accidents c h r o m o s o m i q u e s c o n d u i s a n t à une MHP sont le plus souvent la fécondation d'un ovule haploïde par deux spermatozoïdes haploïdes, c'est la dispermie, ou bien par un spermatozoïde diploïde, c'est la diandrie [11]. La répartition des chromosomes sexuels donne trois types de triploïdies : 69 XXX, 69 XXY, [12].…”

Section: Discussionunclassified

Les môles hydatiformes partielles au Maroc : étude épidémiologique et clinique

Boufettal

Coullin²,

Mahdaoui³

et al. 2012

East Mediterr Health J

View full text Add to dashboard Cite

RÉSUMÉ La présente étude rétrospective a examiné les cas de môle hydatiforme partielle (MHP) diagnostiqués au CHU de Casablanca de 2000 à 2010 et rapporte le profil épidémiologique, clinique, thérapeutique et évolutif de cette entité pathologique. Ont été inclus tous les cas de MHP évoqués échographiquement et cliniquement puis confirmés à l'examen anatomo-pathologique. Nous avons recensé 24 cas de MHP parmi 60 748 accouchements et 1704 avortements spontanés, ce qui donne une fréquence de 0,4 pour 1000 grossesses et 1,4 % des avortements. La moyenne d'âge était de 26 ans (extrêmes 16-55 ans). Les circonstances de découverte clinique et échographique étaient variées : 79,2 % des patientes consultaient pour des métrorragies ; un syndrome thyrotoxicosique clinique était retrouvé chez une patiente (4,2 %). L'examen physique montrait un utérus augmenté de taille dans 83,3 % des cas associé à une masse latéro-utérine dans 25 % des cas. Le diagnostic était étayé par un examen échographique associé à un dosage de β-HCG plasmatique. La confirmation était histologique dans tous les cas et le traitement était une aspiration endo-utérine. La dérive néoplasique a été observée dans un cas (4,2 %) qui a évolué vers la rémission sous chimiothérapie. Partial hydatidiform mole in Morocco: an epidemiological and clinical study ABSTRACT This retrospective study reviewed cases of partial hydatidiform mole (PHM) diagnosed at the University Hospital in Casablanca from 2000 to 2010 in order to examine the epidemiological, clinical, therapeutic and progressive pathological factors associated with PHM. All PHM cases confirmed clinically and sonographically at pathological examination were included. We identified 24 cases of PHM among 60 748 births and 1704 abortions, giving a frequency of 0.4 per 1000 pregnancies and 1.4% of abortions. The mean age was 26 years (range: 16-55 years). The circumstances of discovery and clinical ultrasound varied: 79.2% of patients sought consultation for bleeding; clinical thyrotoxicosis syndrome was found in 1 patient (4.2%). Physical examination showed increased uterine size in 83.3% of cases associated with a latero-uterine mass in 25%. The diagnosis was supported by an ultrasound examination combined with measurement of plasma βHCG. Histological confirmation was made in all cases and treatment was endo-uterine aspiration. Neoplastic drift was observed in 1 case (4.2%) which went into remission with chemotherapy.

show abstract

Shortened duration of human chorionic gonadotrophin surveillance following complete or partial hydatidiform mole: evidence for revised protocol of a UK regional trophoblastic disease unit

Cited by 55 publications

References 3 publications

Update on the diagnosis and management of gestational trophoblastic disease

Update on the diagnosis and management of gestational trophoblastic disease

Gestational Trophoblastic Neoplasia: Experience from a Tertiary Care Center of India

Les môles hydatiformes partielles au Maroc : étude épidémiologique et clinique

Contact Info

Product

Resources

About